Document is current
Any future updates will be listed below
-
Authors
Aoto, Yuya http://orcid.org/0000-0002-8106-9039
Kise, Tomoo
Nakanishi, Koichi
Nagano, China
Horinouchi, Tomoko
Yamamura, Tomohiko
Ishiko, Shinya
Sakakibara, Nana
Shima, Yuko
Morisada, Naoya
Iijima, Kazumoto
Nozu, Kandai
-
Funding
Funding for this research was provided by:
Grants-in-Aid for Scientific Research (17H04189, 19K08726)
Japan Agency for Medical Research and Development (JP19ek0109231h0003, JP19ek0109231h0003)
- License Information
-
More Information
Article History
Received: 10 April 2020
Accepted: 28 June 2020
First Online: 4 July 2020
Compliance with ethical standards
:
: Kazumoto Iijima has received grant support from Daiichi Sankyo Co., Ltd., as well as consulting fees from Takeda Pharmaceutical Company and Kyowa Hakko Kirin Co., Ltd. Kandai Nozu has received lecture fees from Novartis Pharmaceuticals Corporation. Kazumoto Iijima and Kandai Nozu have filed a patent application regarding the development of antisense nucleotides for exon-skipping therapy in Alport syndrome.
: All procedures performed in this study involving human participants were in accordance with the ethical standards of the institutional research committee at Kobe University and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.
: Informed consent was obtained from all of the participants included in the study.
